Jefferies cuts Xenon Pharmaceuticals stock price target on trial pause

Jefferies has increased its price target for Charles River Laboratories International shares to $340 from $305, while keeping the stock's rating at Buy. The firm highlighted the company's long-term strategy, driven by revenue growth expectations and cost efficiencies from its Create the Future initiative. Analysts also noted positive shifts in the business mix and effective cash flow deployment as crucial components of the plan.

Charles River shares have experienced significant growth, rising 84% over the past six months and 97% over the past year, trading near the 52-week high of $303.31. Currently, the stock appears overvalued compared to its estimated Fair Value, as per InvestingPro analysis. Jefferies' research indicates that Charles River Laboratories' future growth prospects stem from multiple avenues, including bioanalysis mergers and acquisitions, artificial intelligence applications, and higher pricing.

The company's Discovery and Safety Assessment segment offers several growth opportunities through these avenues. Jefferies expects Charles River to adopt an integrated portfolio approach rather than a complete overhaul of its existing methods. The investment bank has retained its Buy rating for the stock alongside the raised price target.